An atypical antipsychotic lurasidone potently reverses impairments of learning and memory in an animal model for schizophrenia

被引：0
|
作者：
Enomoto, T.
Ishibashi, T.
Tokuda, K.
Ishiyama, T.
Toma, S.
Ito, A.
机构：
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2006年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S130 / S130
页数：1
相关论文
共 50 条
  • [41] Rivastigmine reverses cognitive deficit and acetylcholinesterase activity induced by ketamine in an animal model of schizophrenia
    Alexandra I. Zugno
    Ricardo Filipe Julião
    Josiane Budni
    Ana Maria Volpato
    Daiane B. Fraga
    Felipe D. Pacheco
    Pedro F. Deroza
    Renata D. Luca
    Mariana B. de Oliveira
    Alexandra S. Heylmann
    João Quevedo
    Metabolic Brain Disease, 2013, 28 : 501 - 508
  • [42] Animal models of working memory: A review of tasks that might be used in screening drug treatments for the memory impairments found in schizophrenia
    Dudchenko, Paul A.
    Talpos, John
    Young, Jared
    Baxter, Mark G.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2013, 37 (09): : 2111 - 2124
  • [43] Reversal Learning Impairments in the Maternal Immune Activation Rat Model of Schizophrenia
    Kleinmans, Maren
    Bilkey, David K.
    BEHAVIORAL NEUROSCIENCE, 2018, 132 (06) : 520 - 525
  • [44] Rivastigmine reverses cognitive deficit and acetylcholinesterase activity induced by ketamine in an animal model of schizophrenia
    Zugno, Alexandra I.
    Juliao, Ricardo Filipe
    Budni, Josiane
    Volpato, Ana Maria
    Fraga, Daiane B.
    Pacheco, Felipe D.
    Deroza, Pedro F.
    Luca, Renata D.
    de Oliveira, Mariana B.
    Heylmann, Alexandra S.
    Quevedo, Joao
    METABOLIC BRAIN DISEASE, 2013, 28 (03) : 501 - 508
  • [45] Escitalopram potently reverses conditioned footshock-induced suppression of exploratory activity in rats - An animal model of generalised anxiety
    Papp, M
    Sanchez, C
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S348 - S349
  • [46] Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs
    Lipska, BK
    Lerman, DN
    Khaing, ZZ
    Weickert, CS
    Weinberger, DR
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2003, 18 (02) : 391 - 402
  • [47] Chronic pubertal cannabinoid treatment as a behavioural model for aspects of schizophrenia: effects of the atypical antipsychotic quetiapine
    Leweke, F. Markus
    Schneider, Miriam
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2011, 14 (01): : 43 - 51
  • [48] Identifying a predictive model for response to atypical antipsychotic monotherapy treatment in south Indian schizophrenia patients
    Gupta, Meenal
    Moily, Nagaraj S.
    Kaur, Harpreet
    Jajodia, Ajay
    Jain, Sanjeev
    Kukreti, Ritushree
    GENOMICS, 2013, 102 (02) : 131 - 135
  • [49] The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review
    Thornton, Allen E.
    Van Snellenberg, Jared X.
    Sepehry, Amir A.
    Honer, William G.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2006, 20 (03) : 335 - 346
  • [50] Subchronic PCP Treatment in Mice Recapitulates Synaptic Proteomic Changes in Schizophrenia Cortex via Effects on CAMK2 and Microtubules and Rescue by Atypical Antipsychotic, Lurasidone
    Meltzer, Herbert
    BIOLOGICAL PSYCHIATRY, 2019, 85 (10) : S369 - S369
12345